1. Name and Address of Reporting Person *
   Davis Robert M
   MERCK & CO., INC.
   2000 GALLOPING HILL ROAD
   KENILWORTH, NJ 07033

2. Issuer Name and Ticker or Trading Symbol
   Merck & Co., Inc. [ MRK ]

5. Relationship of Reporting Person(s) to Issuer
   (Check all applicable)
   ____ Director
   ____ 10% Owner
   ____ Officer (give title below)
   __ Other (specify below)
   EVP, Global Svs & CFO

3. Date of Earliest Transaction (MM/DD/YYYY)
   10/5/2020

6. Individual or Joint/Group Filing (Check Applicable Line)
   _ Form filed by One Reporting Person
   _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Trans. Date</th>
<th>3A. Deemed Execution Date, if any</th>
<th>3. Trans. Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>10/5/2020</td>
<td>M</td>
<td>251273</td>
<td>A</td>
<td>$0</td>
<td>422328.757</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>10/5/2020</td>
<td>S</td>
<td>251273</td>
<td>D</td>
<td>$81.0287 (1)</td>
<td>171055.757 (2)</td>
<td>D</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Trans. Date</th>
<th>3A. Deemed Execution Date, if any</th>
<th>4. Trans. Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$54.68</td>
<td>10/5/2020</td>
<td>M</td>
<td>251273</td>
<td>5/10/2017 (2)</td>
<td>6/9/2026</td>
<td>Common Stock</td>
<td>251273</td>
<td>0</td>
<td>(2)</td>
<td>(3)</td>
</tr>
</tbody>
</table>

Explanation of Responses:
(1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.62 to $81.42, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
(2) Holdings include shares acquired in dividend reinvestment transactions.

Reporting Owners

<table>
<thead>
<tr>
<th>Reporting Owner Name / Address</th>
<th>Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Davis Robert M</td>
<td></td>
</tr>
<tr>
<td>MERCK &amp; CO., INC.</td>
<td></td>
</tr>
<tr>
<td>2000 GALLOPING HILL ROAD</td>
<td></td>
</tr>
<tr>
<td>KENILWORTH, NJ 07033</td>
<td></td>
</tr>
<tr>
<td>EVP, Global Svs &amp; CFO</td>
<td></td>
</tr>
</tbody>
</table>

Signatures

/s/ Jon Filderman as Attorney-in-Fact for Robert M. Davis
10/6/2020

** Signature of Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.